Study of HAIC added on chemotherapy in patients with with unresectable advanced Hepatocellular Carcinoma

Phase 3

Recruiting

• Conditions: nresectable advanced Hepatocellular Carcinoma; Hepatocellular Carcinoma

• Registration Number: JPRN-jRCTs061210065
• Lead Sponsor: Takeuchi Yasuto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1 20 age old over
2 Regardless of gender
3 Less than 1 of performance status
4 Patients who diagnosed with unresectable advanced Hepatocellular Carcinoma
5 Patients who have no treatment history of HAIC with Cisplatin
6 Patients who are getting treatment with Atezolizumab plus Bevacizumab
7 Measurable tumors in the liver
8 Patienst who have been fully informed consent

Exclusion Criteria

1 Patients with Child-Pugh score of 8 points or more
2 Allergy for contrast media
3 Less than 30 mL/min of eGFR
4 Allergy for Cisplatin
5 Allergy for Atezolizumab
6 Allergy for Bevacizumab
7 History of Hemoptysis
8 History of autoimmune disease
9 Interstitial pneumonia
10 Intraperitoneal inflamation or wounded
11 Brain metastasis
12 Congenital hemorrhagic disease
13 Severe Hart failure
14 Being pregnant or possibly pregnant
15 Patients who judged as inappropriate candidate by the chief medical examine

Study & Design

• Study Type: Interventional
• Study Design: Not specified